VKTX - バイキング・セラピュ―ティクス (Viking Therapeutics Inc.)

VKTXのニュース

   Viking Therapeutics to Participate in Fireside Chat at BTIG Biotechnology Conference 2022  2022/08/02 20:05:00 PR Newswire
SAN DIEGO, Aug. 2, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D.,…
   Viking Therapeutics (VKTX) Q2 2022 Earnings Call Transcript  2022/07/28 04:30:49 The Motley Fool
VKTX earnings call for the period ending June 30, 2022.
   Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q2 2022 Results - Earnings Call Transcript  2022/07/27 23:35:02 Seeking Alpha
Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) Q2 2022 Results Conference Call July 27, 2022 04:30 PM ET Company Participants Stephanie Diaz - Manager of Investor Relations Brian Lian -…
   Recap: Viking Therapeutics Q2 Earnings  2022/07/27 22:10:03 Benzinga
Viking Therapeutics (NASDAQ: VKTX ) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Viking Therapeutics missed estimated earnings by 9.52%, reporting an … Full story available on Benzinga.com
   Viking Therapeutics GAAP EPS of -$0.23 misses by $0.02  2022/07/27 20:33:48 Seeking Alpha
Viking Therapeutics press release (VKTX): Q2 GAAP EPS of -$0.23 misses by $0.02.Viking ended the second quarter of 2022 with $169 million in cash, cash equivalents and…
   Viking Therapeutics (VKTX) Q2 2022 Earnings Call Transcript  2022/07/28 04:30:49 The Motley Fool
VKTX earnings call for the period ending June 30, 2022.
   Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q2 2022 Results - Earnings Call Transcript  2022/07/27 23:35:02 Seeking Alpha
Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) Q2 2022 Results Conference Call July 27, 2022 04:30 PM ET Company Participants Stephanie Diaz - Manager of Investor Relations Brian Lian -…
   Recap: Viking Therapeutics Q2 Earnings  2022/07/27 22:10:03 Benzinga
Viking Therapeutics (NASDAQ: VKTX ) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Viking Therapeutics missed estimated earnings by 9.52%, reporting an … Full story available on Benzinga.com
   Viking Therapeutics GAAP EPS of -$0.23 misses by $0.02  2022/07/27 20:33:48 Seeking Alpha
Viking Therapeutics press release (VKTX): Q2 GAAP EPS of -$0.23 misses by $0.02.Viking ended the second quarter of 2022 with $169 million in cash, cash equivalents and…
   Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update  2022/07/27 20:05:00 PR Newswire
Conference call scheduled for 4:30 p.m. ET today Clinical Data From Three Programs Anticipated in Next Twelve Months VK2809 Phase 2b VOYAGE Study Advancing; Completion of Enrollment Expected in 4Q 2022 Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Ongoing; Initial Results Expected by…
   Viking Therapeutics Inc Shares Close in on 52-Week Low - Market Mover  2022/01/09 06:27:14 Kwhen Finance
Viking Therapeutics Inc (VKTX) shares closed today at 0.5% above its 52 week low of $4.18, giving the company a market cap of $328M. The stock is currently down 8.7% year-to-date, down 33.6% over the past 12 months, and up 233.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 26.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 64.5% The company's stock price performance over the past 12 months lags the peer average by 67.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Viking Therapeutics (NASDAQ:VKTX) Shares Cross Below 50-Day Moving Average of $5.61  2021/12/24 08:18:41 ETF Daily News
Viking Therapeutics, Inc. (NASDAQ:VKTX)s share price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $5.61 and traded as low as $4.86. Viking Therapeutics shares last traded at $5.18, with a volume of 841,181 shares. A number of equities analysts have commented on [] The post Viking Therapeutics (NASDAQ:VKTX) Shares Cross Below 50-Day Moving Average of $5.61 appeared first on ETF Daily News .
   Analysts Set Viking Therapeutics, Inc. (NASDAQ:VKTX) PT at $13.93  2021/12/23 23:34:43 Transcript Daily
Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) have been given a consensus rating of Buy by the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued a report on the stock in []
   Viking Therapeutics Inc. (NASDAQ: VKTX): Whats Next In 2021?  2021/12/18 13:00:00 Stocks Register
Viking Therapeutics Inc. (NASDAQ:VKTX) shares, rose in value on Friday, 12/17/21, with the stock price up by 5.59% to the previous days close as strong demand from buyers drove the stock to $4.91. Actively observing the price movement in the last trading, the stock closed the session at $4.65, falling within a range of $4.60 Viking Therapeutics Inc. (NASDAQ: VKTX): Whats Next In 2021? Read More »
   Metropolitan Life Insurance Co NY Increases Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)  2021/12/06 09:46:41 Dakota Financial News
Metropolitan Life Insurance Co NY grew its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 47,695.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,559 shares of the biotechnology companys stock after buying an additional 9,539 shares during the quarter. Metropolitan Life []

calendar